X4 Pharmaceuticals, Inc. (NASDAQ:XFOR) Q4 2020 Results Earnings Conference Call March 4, 2021 8:30 AM ET Company Participants Daniel Ferry - LifeSci Advisors Paula Ragan - Chief Executive Officer Adam Mostafa - Chief Financial Officer Dr. Diego Cadavid - Chief Medical Officer Art Taveras - Chief Scientific Officer Mary DiBiase - Senior Vice-President, Technical Operations and Quality Conference Call Participants Stephen Willey - Stifel Joel Beatty - Citi Leland Gershell - Oppenheimer Swayampakula Ramakanth ...

X4 Pharmaceuticals, Inc. (NASDAQ:XFOR) Q3 2020 Earnings Conference Call November 5, 2020 8:30 AM ET Company Participants Candice Ellis - Director of Corporate Communications and Investment Relations Paula Ragan - Chief Executive Officer Adam Mostafa - Chief Financial Officer Conference Call Participants Arlinda Lee - Canaccord Laura Christianson - Cowen Zegbeh Jallah - ROTH Capital Operator Greetings and welcome to X4 Pharmaceuticals Third Quarter Financial and Operating Results Conference Call. [Operator ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 _____________________________________________________________________________________ FORM 10-Q _____________________________________________________________________________________ (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2020 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the trans ...

INVESTOR PRESENTATION SEPTEMBER 2020 X4 PHARMACEUTICALS INVESTOR DECK FORWARD LOOKING STATEMENTS The statements herein are subject to various risks and uncertainties. These risks and uncertainties include, without limitation, the risk that trials and studies may be delayed and may not have satisfactory outcomes; potential adverse effects arising from the testing or use of mavorixafor or other product candidates; the risk that costs required to develop mavorixafor or other product candidates or to expand our ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 _____________________________________________________________________________________ FORM 10-Q _____________________________________________________________________________________ (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2020 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition ...

X4 Pharmaceuticals, Inc. (NASDAQ:XFOR) Q2 2020 Earnings Conference Call July 30, 2020 8:30 AM ET Company Participants Candice Ellis - Director, Corporate Communications & Investor Relations Paula Ragan - Chief Executive Officer Adam Mostafa - Chief Financial Officer Conference Call Participants Ellen Sands – Stifel Ben Shim – Canaccord Leland Gershell - Oppenheimer Joel Beatty - Citi Swayampakula Ramakanth - H.C. Wainwright Laura Christianson - Cowen Zegbeh Jallah - ROTH Capital Partners Mayank Mamtani - B. ...

INVESTOR PRESENTATION JUNE 2020 X 4 P H A R M A C E U T I C A L S I N V E S T O R D E C K FORWARD LOOKING STATEMENTS The statements herein are subject to various risks and uncertainties. These risks and uncertainties include, without limitation, the risk that trials and studies may be delayed and may not have satisfactory outcomes; potential adverse effects arising from the testing or use of mavorixafor or other product candidates; the risk that costs required to develop mavorixafor or other product candida ...

EHA 2020 Poster Highlights June 12, 2020 Safe Harbor Statement 2 This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended. The words "may," "will," "could," "would," "should," "expect," "plan," "anticipate," "intend," "believe," "estimate," "predict," "project," "potential," "continue," "target" and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain th ...

INVESTOR PRESENTATION JUNE 2020 X4 PHARMACEUTICALS INVESTOR DECK FORWARD LOOKING STATEMENTS The statements herein are subject to various risks and uncertainties. These risks and uncertainties include, without limitation, the risk that trials and studies may be delayed and may not have satisfactory outcomes; potential adverse effects arising from the testing or use of mavorixafor or other product candidates; the risk that costs required to develop mavorixafor or other product candidates or to expand our oper ...

X4 Pharmaceuticals, Inc. (NASDAQ:XFOR) Q1 2020 Earnings Conference Call May 7, 2020 8:30 AM ET Company Participants Candice Ellis - Director of Corporate Communications & Investor Relations Paula Ragan - Chief Executive Officer Adam Mostafa - Chief Financial Officer Conference Call Participants Stephen Willey - Stifel Joel Beatty - Citi Swayampakula Ramakanth - H.C. Wainwright Laura Christianson - Cowen Trevor Allred - Oppenheimer Sahil Kazmi - B. Riley FBR Arlinda Lee - Canaccord Operator Greetings, and w ...